U.S. flag

An official website of the United States government

Display Settings:

Items per page
You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 18

1.
1.1

1.1. Analysis. From: Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

Comparison 1: IVIG vs control, Outcome 1: CAAs. All total doses. All Children.

Richmal M Oates-Whitehead, et al. Cochrane Database Syst Rev. 2003 Oct;2003(4):CD004000.

CitationFull text

2.
1.10

1.10. Analysis. From: Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

Comparison 1: IVIG vs control, Outcome 10: Duration of fever

Richmal M Oates-Whitehead, et al. Cochrane Database Syst Rev. 2003 Oct;2003(4):CD004000.

CitationFull text

3.
1.8

1.8. Analysis. From: Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

Comparison 1: IVIG vs control, Outcome 8: CAAs. 600 mg/kg total dose. All children

Richmal M Oates-Whitehead, et al. Cochrane Database Syst Rev. 2003 Oct;2003(4):CD004000.

CitationFull text

4.
1.7

1.7. Analysis. From: Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

Comparison 1: IVIG vs control, Outcome 7: CAAs. 500 mg/kg total dose. All children

Richmal M Oates-Whitehead, et al. Cochrane Database Syst Rev. 2003 Oct;2003(4):CD004000.

CitationFull text

5.
1.9

1.9. Analysis. From: Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

Comparison 1: IVIG vs control, Outcome 9: CAAs. 1200 mg/kg total dose. All children

Richmal M Oates-Whitehead, et al. Cochrane Database Syst Rev. 2003 Oct;2003(4):CD004000.

CitationFull text

6.
1.6

1.6. Analysis. From: Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

Comparison 1: IVIG vs control, Outcome 6: CAAs. 100 mg/kg total dose. All children

Richmal M Oates-Whitehead, et al. Cochrane Database Syst Rev. 2003 Oct;2003(4):CD004000.

CitationFull text

7.
1.3

1.3. Analysis. From: Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

Comparison 1: IVIG vs control, Outcome 3: CAAs. All total doses. Only children with CAAs at diagnosis.

Richmal M Oates-Whitehead, et al. Cochrane Database Syst Rev. 2003 Oct;2003(4):CD004000.

CitationFull text

8.
1.2

1.2. Analysis. From: Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

Comparison 1: IVIG vs control, Outcome 2: CAAs. All total doses. Excluding children with CAAs at diagnosis

Richmal M Oates-Whitehead, et al. Cochrane Database Syst Rev. 2003 Oct;2003(4):CD004000.

CitationFull text

9.
2.2

2.2. Analysis. From: Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

Comparison 2: Comparison of dose regimens, Outcome 2: 100 mg/kg x 5 days vs 400 mg/kg x 5 days

Richmal M Oates-Whitehead, et al. Cochrane Database Syst Rev. 2003 Oct;2003(4):CD004000.

CitationFull text

10.
2.3

2.3. Analysis. From: Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

Comparison 2: Comparison of dose regimens, Outcome 3: 200 mg/kg x 5 days vs 400 mg/kg x 5 days

Richmal M Oates-Whitehead, et al. Cochrane Database Syst Rev. 2003 Oct;2003(4):CD004000.

CitationFull text

11.
1.5

1.5. Analysis. From: Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

Comparison 1: IVIG vs control, Outcome 5: CAAs. All total doses. No CAAs at enrollment. Studies using recognised diagnostic criteria.

Richmal M Oates-Whitehead, et al. Cochrane Database Syst Rev. 2003 Oct;2003(4):CD004000.

CitationFull text

12.
2.1

2.1. Analysis. From: Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

Comparison 2: Comparison of dose regimens, Outcome 1: 100 mg/kg x 5 days vs 200 mg/kg x 5 days

Richmal M Oates-Whitehead, et al. Cochrane Database Syst Rev. 2003 Oct;2003(4):CD004000.

CitationFull text

13.
1.4

1.4. Analysis. From: Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

Comparison 1: IVIG vs control, Outcome 4: CAAs. All total doses. All children. Studies using recognised diagnostic criteria.

Richmal M Oates-Whitehead, et al. Cochrane Database Syst Rev. 2003 Oct;2003(4):CD004000.

CitationFull text

14.
2.5

2.5. Analysis. From: Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

Comparison 2: Comparison of dose regimens, Outcome 5: Fever 200 mg/kg x 3 days vs 400 mg/kg/day x 3 days

Richmal M Oates-Whitehead, et al. Cochrane Database Syst Rev. 2003 Oct;2003(4):CD004000.

CitationFull text

15.
3.2

3.2. Analysis. From: Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

Comparison 3: Type of IVGG comparisons, Outcome 2: Intact vs pepsin treated IVIG ‐ Coronary artery abnormalities 31‐60 days

Richmal M Oates-Whitehead, et al. Cochrane Database Syst Rev. 2003 Oct;2003(4):CD004000.

CitationFull text

16.
2.4

2.4. Analysis. From: Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

Comparison 2: Comparison of dose regimens, Outcome 4: 400 mg/kg x 5 days vs 2 gm/kg single dose

Richmal M Oates-Whitehead, et al. Cochrane Database Syst Rev. 2003 Oct;2003(4):CD004000.

CitationFull text

17.
3.3

3.3. Analysis. From: Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

Comparison 3: Type of IVGG comparisons, Outcome 3: Intact vs pepsin treated IVIG ‐ Coronary artery abnormalities ‐ 180+ days

Richmal M Oates-Whitehead, et al. Cochrane Database Syst Rev. 2003 Oct;2003(4):CD004000.

CitationFull text

18.
3.1

3.1. Analysis. From: Intravenous immunoglobulin for the treatment of Kawasaki disease in children.

Comparison 3: Type of IVGG comparisons, Outcome 1: Intact vs pepsin treated IVIG ‐ Coronary artery abnormalities 0‐30 days

Richmal M Oates-Whitehead, et al. Cochrane Database Syst Rev. 2003 Oct;2003(4):CD004000.

CitationFull text

Display Settings:

Items per page

Supplemental Content

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center